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Abstract
Purpose: In this contribution we try to find new indicators to measure characteristics of a 
firm’s patents and their influence on a company’s profits.
Design/methodology/approach: We realize that patent evaluation and influence on a 
company’s profits is a complicated issue requiring different perspectives. For this reason we 
design two types of structural h-indices, derived from the International Patent Classification 
(IPC). In a case study we apply not only basic statistics but also a nested case-control 
methodology.
Findings: The resulting indicator values based on a large dataset (19,080 patents in total) 
from the pharmaceutical industry show that the new structural indices are significantly 
correlated with a firm’s profits. 
Research limitations: The new structural index and the synthetic structural index have just 
been applied in one case study in the pharmaceutical industry.
Practical implications: Our study suggests useful implications for patentometric studies and 
leads to suggestions for different sized firms to include a healthy research and development 
(R&D) policy management. The structural h-index can be used to gauge the profits resulting 
from the innovative performance of a firm’s patent portfolio.
Originality/value: Traditionally, the breadth and depth of patents of a firm and their citations 
are considered separately. This approach, however, does not provide an integrated insight in 
the major characteristics of a firm’s patents. The Sh(Y) index, proposed in our investigation, 
can reflect a firm’s innovation activities, its technological breadth, and its influence in an 
integrated way.
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1 Introduction
The technological scope of a firm’s patents, as expressed by the number and 
nature of the classes to which these patents are assigned, is an important element to 
describe the relation between a company’s technological diversity and its profits 
(Chen, Jang, & Wen, 2010; Chiu, et al., 2010; Olivo et al., 2011). Indeed, research 
suggests that the scope of patents owned by a firm has a strong impact on performance 
and is, as such, an economically significant variable (Lerner, 1994; Reitzig, 2003). 
As we want to take an international point of view we use the International Patent 
Classification (IPC) codes, but not American or European patent codes. Moreover, 
IPC codes have already been used in several other investigations (Chen, Jang, & 
Wen, 2010; Chiu et al., 2010; Lerner, 1994; Sapsalis, van Pottelsberghe de la 
Potterie, & Navon, 2006). Following these colleagues we use the number of 3- or 
4-digit IPC codes assigned to a patent as a proxy of its technological breadth. 
Besides, the depth of a patent is also a structural element involved in a patent 
portfolio. Consider, for example, an IPC code such as “A61K-037”: the head 3 to 
4 digits refer to a technological class and subclass (A61K), and the tail digits reflect 
the technological depth of the patent involved (037). This suggests that at the 
structural level, the breadth of patent is the primary structure, and the depth of a 
patent is the secondary one.
The ratio between the total number of codes (7- or 8-digit codes) used to describe 
patent p and the number of classes and subclasses, reflected by 3- or 4-digit codes, 
is called its technological depth, denoted as d(p). It is at least one and usually strictly 
larger than one. This indicator is not very precise because the number of 7- and 
8-digit IPC codes is quite different per class (Lodh & Battaggion, 2014; Zhang, 
Chen, & Niu, 2012).
Generally, the broader the scope of a patent, the larger the number of competing 
products and processes that might infringe on the patent (Merges & Nelson, 1990). 
In this context, these authors pointed out that excessively broad patents may lead 
to use by other parties. Yet, Gilbert and Shapiro (1990) claimed that broader patents 
provide inventors with a greater ability to earn profits. As the competitive strength 
of a firm’s patents is an aspect of their market value, technological value, and social 
value, finding the optimal depth and breadth of a patent is a complex as well as a 
controversial topic (Guan & Gao, 2009; Hu & Rousseau, 2015; Hu, Rousseau, & 
Chen, 2012; Klemperer, 1990; Lee, 2009; Palokangas, 2011; Reitzig, 2003). We 
recall that, according to Gilbert and Shapiro (1990), the breadth of a patent is related 
to the flow of profits available to the patentee as well as to the minimum improvements 
that another inventor has to make in order to obtain a non-infringing patent. 
According to Lerner (1994) the market value of patents, sometimes even of a single 
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patent, can have a major effect on the value of a firm. Exploring the optimal depth 
and breadth of a patent, researchers have increasingly recognized the importance to 
focus on the breadth of a patent (Denocolò, 1996; Kanniainen & Stenbacka, 2000; 
Merges & Nelson, 1990; Palokangas, 2011).
Continuing our research on the characteristics of the IPCh indicator (Hu & 
Rousseau, 2015) (its definition is recalled further on), the purpose of this contribution 
is:
1)  To show, using a large dataset, how the IPCh indicator for patents is able to 
provide information on a company’s innovative activities;
2)  To provide convincing evidence that the IPCh and the yearly h-index of 
patents are closely related to a firm’s innovative performance, and compare 
this with a synthetic indicator including the depth of a patent, based on 
companies in the pharmaceutical industry; and
3)  To provide a simple way to gauge a firm’s patent performance by jointly 
taking two h-type indices into account, each reflecting another aspect of the 
h-core in the lists of technological breadth and citations (reflecting market 
value and technological value). 
As we are aware of the shortcomings of all h-type indices (Bouyssou & Marchant, 
2011; Waltman & van Eck, 2012), we nevertheless claim that our approach is a 
useful addition to the patent toolbox. Moreover, no indicator on its own can provide 
information from all possible perspectives at the same time. Borrowing the 
terminology of Valiant (2013), proposed by him in the context of machine learning, 
the information provided by such an indicator is at best Probably Approximately 
Correct (PAC). 
2  A Short Literature Review Related to the Concepts Used in This 
Contribution
2.1 The General h-index Idea 
Hirsch (2005) proposed the h-index as an author-level indicator combining 
productivity (published articles) and impact (received citations). Soon his idea was 
applied to other source-items relations such as journal publications and citations 
(Braun, Glänzel, & Schubert, 2005), a company’s patent assignments and their 
citations in other patents (Guan & Gao, 2009), publications and citations of topics, 
restricted to recent years (Banks, 2006) or availability of books and their loans 
according to a library classification (Liu & Rousseau, 2009). We first recall the basic 
mechanism for calculating the h-index of an actor (author, company, or a journal). 
One considers a two-dimensional table of sources and items, where sources, e.g. 
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publications or patents, are ranked according to items, e.g. received citations. 
Sources with the same number of items are given different rankings, but the exact 
order does not matter. Then actor A’s h-index is equal to the number h if the first h 
sources have each at least h items, while the source ranked h+1 has strictly less than 
h+1 items.
2.2 Patent Analysis
The relation between the breadth and depth of its patents on the one hand, and 
the health of a firm on the other, has been studied for several decades (Denicolò, 
1996; O’Donoghue, Scotchmer, & Thisse, 1998; Palokangas, 2011; Prencipe, 2000; 
Wang & von Tunzelmann, 2000). Yet, no final answer about the optimal breadth 
and depth of patents has been found (Ozman, 2007; Zhang, Chen, & Niu, 2012; 
Lodh & Battaggion, 2014; Breschi, Lissoni, & Malerba, 2003). When using diversity 
indexes to measure the technological breadth and depth of a firm, it may happen 
that results are biased downwards for small and medium-sized firms for which the 
scale of technological activities is small (Chen, Jang, & Wen, 2010; Hu & Rousseau, 
2015; Miller, 2006; Palokangas, 2011). Moreover, diversity indices such as the Rao-
Stirling index may show cyclical patterns that are not related to a company’s profits 
but are rather related to the number of inventors (Leydesdorff, 2015). This suggests 
that if one wants to understand the optimal breadth and depth of patents, an approach 
different from the “complexity and diversity” might be worth investigating (Lodh 
& Battaggion, 2014; Wang & von Tunzelmann, 2000).
Traditionally, the breadth and depth of patents of a firm and their citations are 
considered separately. This approach, however, does not provide an integrated 
insight in the major characteristics of a firm’s patents. It has been observed that 
return on investment of a patent depends largely on a firm’s market value and its 
technological value, while the competitive strength of a firm’s patents bears a close 
relation to market value, technological value, social value of patents, and healthy 
management styles (Guan & Gao, 2009; Hu & Rousseau, 2015; Lee, 2009; 
Palokangas, 2011). 
3 Methodology 
We develop a new approach to gauge a firm’s innovative performance based on 
the following insights.
3.1 Potential Applications of Patents
We claim that one of the most important elements affecting the potential 
applications of a patent is its breadth, operationalized by codes, such as the IPC, the 
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U.S. Patent Classification System (USPC), Cooperative Patent Classification (CPC) 
or the European Patent Office (EPO) codes assigned to it. This set of codes forms 
a basic aspect to grant its owner either a very limited right to exclusive use or a 
more general right covering a variety of different realizations of the invention 
(Reitzig, 2003). This fact implies that patents can differ with respect to the degree 
of protection afforded to an invention (Gilbert & Shapiro, 1990; Klemperer, 1990). 
In this context we note that accrediting codes to a patent is an arena in which patent 
examiners exercise wide discretion. In general, the broader the patent, the higher 
the chance to be applied in different practical fields and the larger the potential 
profits to the firm or a purchaser of the firm’s patent (Palokangas, 2011). This leads 
to the claim that the optimal breadth of patents should focus on a firm’s performance. 
Excessively broad patent claims increase the patentees’ non-market related risks 
from rivals and provide them with little flexibility to face unexpected situations 
(Merges & Nelson, 1990). However, the narrower a patent’s claims, the more the 
patentee may be victim of imitation as very similar products may lie outside the 
original patent’s claims (Denicolò, 1996; Kanniainen & Stenbacka, 2000).
A firm which focuses on excessively broad patents would overspend its research 
and development (R&D) capital by developing or buying an overly large number 
of patents. And, vice versa, if most of the firm’s patents are of narrow breadth, the 
firm reduces its chance to earn larger profits than competitors. Obviously, these two 
extreme cases do not lead to healthy management styles in a competitive industry. 
Therefore, it is very important to measure the competitive strength of patents and 
hence the “weight” of a firm’s patent portfolio. Such an investigation must include 
the number of patents, their impact and their breadth. 
3.2  The Structure of Patents and Their Influence Must Jointly Be Taken 
into Account
It is well known that the received number of patent citations is an important 
indicator to measure the influence of a patent. Moreover, patent citations have a 
positive relation with the profits of the patent owner (Hu, Rousseau, & Chen, 2012; 
Trajtenberg, 1990). 
Many investigations point out that, compared to the breadth of a patent (the 
primary dimension), it is less meaningful to focus on the depth of a patent because 
the determination of a patent’s depth is just approximate and no positive relation 
between a patent’s performance and its depth has been found (Gilbert & Shapiro, 
1990; Kanniainen & Stenbacka, 2000; Klemperer, 1990; Lodh & Battaggion, 2014; 
Ozman, 2007; Palokangas, 2011; Reitzig, 2003; Zhang, Chen, & Niu, 2012).
Grönqvist (2009) argues that broader patents are not necessarily more valuable 
than narrower ones. Concretely, patents described with many codes do not necessarily 
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lead to a larger profit for the firm. Therefore, neither the breath of patents nor the 
number of received citations on their own are clear-cut indicators for the value of 
a company’s patent portfolio. If we want to understand the competitive strength of 
a firm from the perspective of patent performance, the primary structure of patents 
(patent breadth), the secondary structure (patent depth), and their influence should 
jointly be taken into account in a multi-layered approach (Denicolò, 1996; Hu, 
Rousseau, & Chen, 2012; Palokangas, 2011). Abstractly, their relationships can be 
described with Equation (1):
 SP = f (p,bp,dp,cp), (1)
where SP denotes the competitive strength of patent-related performance of a firm, 
and p is the number of patents; bp denotes their breadth, dp their depth and cp the 
number of received citations.
3.3 The Structural h-index for Patents 
To reveal the relation between the essential structure of patents and their 
competitive strength, e.g. profit performance, in the real world, and clarify the 
controversy on the influence of depth on a patent’s profit, we propose two types of 
structural h-indices for patents: (1) the structural h-index, a primary one, combining 
the number of patents with the primary structure (breadth of patent) and with 
forward, i.e. received, citations; (2) the synthetic structural h-index, using the 
number of patents, the breadth and depth of these patents, and the number of forward 
citations.
Hence, we hypothesize that the primary structure of patents (patent breadth) and 
their influence on a firm can be measured by a structural h-type index, combining 
different aspects in a dynamic way.
3.4 Definitions of IPCh and Yearly h-index
A firm’s innovation activities are operationalized as the number of patents, while 
their technological breadth is operationalized by the number of 3- or 4-digit IPC 
codes. Consider a set of patents granted to a firm in a certain year Y, ranked in 
decreasing order of the number of 3- or 4-digit IPC codes assigned to them. Then 
the IPC h-index of this firm in the year Y is equal to q if q is the highest rank such 
that the first q patents are assigned to at least q IPC codes (Hu & Rousseau, 2015). 
The resulting indicator is denoted as IPCh3 or IPCh4 depending on the number of 
digits that have been used.
Next, we define a yearly h-index slightly modified from the original meaning of 
Hirsch (2005) to map a firm’s innovation activities and influence in the year Y. The 
yearly h-index of a firm in the year Y, denoted as hY, is equal to h if h is the largest 
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rank such that the first h patents receive each at least h citations within a given 
citation window. In the examples investigated below the citation windows always 
end on May 20, 2014.
3.5 Definition of the Patent Depth Yearly h-index (DhY)
Next, we define the yearly h-index of patent depth in the year Y, denoted as DhY 
as follows. Consider the set of patents granted to a firm in the year Y, ranked in 
decreasing order of their technological depth index, d(p). The DhY index of this firm 
in the year Y is equal to k if k is the highest rank such that the first k patents have 
at least a technological depth equal to k. 
3.6 The Structural h-index for Patents
We define the structural h-index for patents granted in the year Y, denoted as 
Sh(Y), as a combination, actually a multiplication, of the IPCh and the yearly patent 
h-index. Hence Sh(Y) can be calculated with Equation (2):
 Sh(Y) = IPChs × hY , (2)
where s = 3 or 4. Moreover, although not indicated in the notation, Sh(Y) is time 
dependent, i.e. depends on the citation window, which in our examples ends on 
May 20, 2014. The Sh(Y) sequence shows a firm’s innovation activities and their 
technological breadth, as well as the influence of patents (by citations) in each year. 
As such we claim that it can be used to gauge the “primary weight” of a firm’s 
patents. This claim is investigated in the next section.
3.7 The Synthetic Structural h-index for Patents
Finally, we define the synthetic structural h-index for patents granted in the year 
Y, denoted as SSh(Y), as a summary indicator constructed from the IPCh, the yearly 
patent h-index (hy), and the patent depth yearly h-index and it can be calculated with 
Equation (3):
 SSh(Y) = w1IPChs + w2hy + w3Dhy , (3)
where w1, w2 and w3 are positive weights such that w1 + w2 + w3 = 1.
4  An Application and an Empirical Study in the Pharmaceutical 
Industry
We recall that the pharmaceutical industry is a high-tech industry in which a 
firm’s performance (and profit) is closely connected to the market value of its 
patents (Hu, Rousseau, & Chen, 2012; Chen, Shih, & Chang, 2013). Therefore, the 
pharmaceutical field is a good test bed to study the practical value of the new 
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indicators Sh(Y) and SSh(Y). We intend to find out if these two indicators are indeed 
able, as we hypothesize, to detect the “weight” of a firm’s patents through their 
relation to a firm’s profits.
4.1 Choice of Firms
The general range of firms acceptable for our purposes contains those 
pharmaceutical companies listed in Fortune 500 2006–2010 issued by the 
CNNMoney website. These companies are the primary focus of our investigation, 
because yearly ranks for “pharmaceutical industry” are available during these years. 
As there are many invisible factors affecting the performance of patents, we try 
to control for external variables by considering the following criteria for inclusion 
in our case study.
1)  Firm location: Different countries have different regulations for patents 
which may influence realized profits (Chen, Shih, & Chang, 2013). For this 
reason only US companies were selected.
2)  Firm internationality: Prior literature has found that there is a significant 
effect of firm scale on profits (Chen, Jang, & Wen, 2010). Accordingly, only 
US-based multinational firms included in Fortune 500 qualify.
3)  Firm age: It has been shown that, in terms of innovation activities, older 
firms have a stronger foundation than younger ones. Hence, a firm’s age 
influences the outcome of its patents’ performance. For this reason we 
included only firms founded before the year 1990 (Banerjee & Cole, 2010; 
McMillan & Thomas, 2005). 
4)  Patent age: As the time between applying for a pharmaceutical patent and its 
return on investment is generally between 8 and 12 years, with 5 years as a 
strict minimum (ISTIS, 2003), and the protection period given by a patent is 
at most 20 years (WIPO, 2000), care must be exerted to take these facts into 
account (Chen, Jang, & Wen, 2010; Hu, Rousseau, & Chen, 2012). For this 
reason, we included only patents granted during the period 1990–2005, and 
considered profits reported by Fortune 500 for the period 2006–2010. 
Taking all these requirements into account resulted in eight US-based multinational 
pharmaceutical companies meeting all the criteria, namely Johnson & Johnson, 
Pfizer, Merck, Bristol-Myers Squibb, Amgen, Genzyme, Allergan and Biogen Idec.
4.2 Data Collection and Processing
We extracted from the Derwent Innovations Index (DII) all patents granted to 
these eight companies during the period 1990 – 2005. For each record we downloaded 
  http://money.cnn.com/magazines/fortune/fortune500/
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all fields, including IPC-codes and citations received (so-called forward citations). 
Data were extracted on 20/05/2014. This led to a total of 19,080 patents for the eight 
firms. Next, we collected the yearly profits for each company as reported by Fortune 
500 2006–2010.
For the dataset of a company’s patents, we first counted the number of 4-digit 
IPC codes for each record via a simple program written by ourselves, and determined 
the yearly IPCh and yearly h-index during 1990–2005 for each company (Appendix 
Tables A1–A3). Then, we calculated the yearly Sh(Y) and yearly SSh(Y) for each firm 
according to Equations (2) and (3). As the breadth of a patent is a primary structure 
while its depth is a secondary one, and because research suggests that both breadth 
and number of citations have positive relations with the profits of the patent owner, 
we take all these factors into account. Moreover, as previous research pointed out 
that 4-digit codes and citation-weighted counts can be taken as “patent-equivalents” 
(Miller, 2006), we – tentatively – weighted them higher than DhY according to a 
weight of 0.4 for IPCh and for hY, and a weight of 0.2 for Dhy in Equation (3) 
(Appendix Table A4).
To compare results based on 3-digit IPC codes with those based on 4-digit codes, 
we also collected the number of 3-digit codes for each patent (Appendix Tables A2 
and A3), and calculated the corresponding Sh index.
4.3 Statistical Methods
To observe the relationship between the Sh(Y) and a firm’s profits, we use two 
different statistical methods:
1)  We calculated the Spearman rank correlation coefficient between the eight 
companies, mean Sh(Y) and mean SSh(Y) values and total profits over the 
period from 2006 to 2010.
2)  A nested case-control (NCC) study. This type of study is an observational 
study whereby a case-control approach is employed within an established 
cohort (Bornehag et al., 2004). This is a popular and valid approach in 
medical studies for small-sample investigations. As such we consider it also 
suitable to our study. The nested case control model as applied in medical 
investigations is less expensive, but less efficient than a full-cohort analysis. 
However, it has been shown that with four controls per case and/or stratified 
sampling of controls, relatively little efficiency may be lost (Goldstein & 
Zhang, 2009).
To apply the NCC method, the eight companies are grouped according to their 
profits: Group H (high profit) consists of the four companies with the highest profit; 
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Group L (low profit) consists of the four companies with the lowest profits. For 
each group, we re-rank companies by their profits in a descending way and denote 
them GHR1, GHR2, GHR3, GHR4, GLR1, GLR2, GLR3, and GLR4 (Table 1). In 
this way, case-control is performed between four control-pairs of companies with 
the same rank order in the respective groups (such as GHR1 vs GLR1), and the 
nested control is designed by a sequence of time points, that is, yearly Sh and yearly 
SSh among controlled cases between two groups during the period 1990–2005. 
Hence, 16 time points in total are used as observations. We recall that the Sh(Y) 
indicator is time dependent. For example, in our case, the Sh(Y) of the year 1990 
has a citation window from the year 1990 to May 20, 2014, and the Sh(Y) in the 
year 1991 has a citation window from the year 1991 to May 20, 2014, and so on. 
As pointed out above, such a stratified sampling of controls can lead to an efficient 
result. 
Table 1. Controlled cases design for companies included in NCC study.
Group H Group L
Company Code Profits* Rank Company Code Profits Rank
Johnson & Johnson GHR1 11,451.00 1 Amgen GLR1 3718.20 1
Pfizer GHR2 10,461.00 2 Biogen Idec GLR2  554.10 2
Merck GHR3 6,610.02 3 Allergan GLR3  395.24 3
Bristol-Myers Squibb GHR4 4,521.80 4 Genzyme GLR4  349.72 4
Note. *Profits 2006–2010 in millions of US dollars (average per year).
Then, we compare the yearly Sh and yearly SSh for each company during the 
period 1990–2005 between two groups using a Paired Samples Test, where pairs 
consist of a company from GH and a corresponding company from GL, as a so-called 
‘control’. 
4.4 Results
In this section, we present the results obtained from our analysis of the 19,080 
patents. We will show that the two types of structural h-indices Sh(Y) and SSh(Y) 
have significant correlations with a firm’s profits as given by Fortune 500 2006–
2010. Moreover, the Sh(Y) index has more significance than SSh(Y).
4.4.1 Yearly Values of Sh for Eight Companies during 1990–2005
Tables 2 and 3 show the resulting yearly Sh values. We would like to point out 
that the rank order of these eight companies is different from those obtained from 
the IPCh and from the h-indices separately (Appendix Tables A1–A3). We consider 
Sh to represent the primary competitive strength of a firm’s patents. 
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Table 2. Yearly Sh indices of eight companies during the period 1990–2005 (using IPCh4).
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 192 161 150 85 32 1 44 12
1991 174 144 186 138 72 0 100 12
1992 145 162 224 100 40 1 100 20
1993 224 132 256 125 35 1 76 12
1994 217 150 240 182 78 30 85 35
1995 240 108 240 162 84 4 92 35
1996 328 120 280 156 84 4 84 84
1997 312 140 264 138 128 30 95 70
1998 280 174 280 174 120 66 70 90
1999 240 196 272 192 78 35 56 96
2000 203 240 200 203 98 70 64 90
2001 189 208 208 186 120 60 130 78
2002 273 252 240 208 140 91 115 60
2003 234 175 333 189 136 56 108 60
2004 210 132 296 189 105 66 90 66
2005 288 108 270 114 91 56 102 30
Mean 234.31 162.63 246.19 158.81 90.06 35.69 88.19 53.13
Rank 2 3 1 4 5 8 6 7
Table 3. Yearly Sh indices of eight companies during the period 1990–2005 (using IPCh3).
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 160 92 100 68 24 1 33 8
1991 145 120 155 92 36 0 80 12
1992 116 108 160 80 30 1 80 15
1993 160 88 192 100 21 1 57 8
1994 155 100 180 104 39 18 51 21
1995 150 54 150 108 56 4 69 21
1996 246 96 175 104 56 4 63 56
1997 234 80 198 92 64 24 57 56
1998 200 116 175 116 75 44 42 60
1999 160 112 204 128 52 21 42 64
2000 145 150 150 116 70 56 48 60
2001 135 104 130 124 60 40 78 52
2002 195 140 180 130 70 52 69 40
2003 156 100 222 135 85 40 72 40
2004 150 88 222 108 60 44 72 44
2005 216 72 210 95 65 40 68 15
Mean 170.19 101.25 175.19 106.25 53.94 24.375 61.31 35.75
Rank 2 4 1 3 6 8 5 7
4.4.2 Yearly Values of SSh for Eight Companies during 1990–2005
Table 4 shows the yearly values of the synthetic structural h-indices for eight 
companies. Note that SSh(Y) combines the IPCh, the yearly patent h-index, and the 
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yearly h-index of patent depth. Therefore, it reflects the first ranked patents in three 
essential dimensions. We may say that SSh(Y) represents the essential competitive 
strength of a firm’s patents. It turns out that the ranks of the mean SSh(Y) for eight 
companies are very similar to those according to Sh(Y). Only the first and the second 
company change places.
Table 4. Yearly SSh indices of eight companies during the period 1990–2005 (using IPCh4).
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 15.8 11.396 13.4 9.4 5.4 1.0  6.4 3.2
1991 14.8 11.812 15.8 12.4 7.8 0.0 10.8 3.2
1992 14.4 12.740 16.8 10.6 6.4 1.0 10.6 4.2
1993 16.2 10.836 17.2 12.8 5.6 1.0 10.0 3.2
1994 15.8 12.188 17.2 14.0 8.4 4.8  9.4 5.4
1995 16.0 8.804 16.4 14.2 8.6 1.8 11.6 5.4
1996 20.4 11.852 18.4 13.6 8.8 1.8 10.6 8.8
1997 19.6 10.044 17.6 12.8 10.8 5.0 10.4 8.4
1998 20.4 14.004 18.2 14.8 10.4 7.4  8.2 9.4
1999 20.2 13.544 17.8 16.4 8.6 5.2  8.0 10.0
2000 16.2 14.656 14.4 15.6 9.6 8.4  8.6 9.8
2001 15.6 13.364 15.0 16.0 10.4 7.2 13.0 8.8
2002 19.2 14.024 16.6 15.6 11.2 9.0 12.0 7.4
2003 15.0 12.876 20.0 15.0 11.6 6.6 10.4 7.6
2004 16.0 11.344 19.6 15.0 10.2 7.6 10.0 8.0
2005 18.8 9.868 17.2 11.2 9.6 6.8 10.0 5.2
Mean 17.15 12.085 16.975 13.713 8.963 4.663 10 6.75
Rank 1 4 2 3 6 8 5 7
4.4.3 Correlations between Sh and SSh and a Firm’s Profits
Table 5 shows the rank correlations between yearly Sh(Y) and yearly SSh(Y) and 
firms’ profits for the eight pharmaceutical companies under study. The Sh and SSh 
values refer to the years 1990–2005, and firms’ profits refer to the period, 2006–
2010. The Spearman rank correlation coefficient between the yearly Sh and a firm’s 
profits is 0.857 (p = 0.007) when using IPCh4, and is 0.762 (p = 0.028) calculated 
by IPCh3. These results mean that the correlations can be described as “very strong”. 
We note that Sh(Y) based on IPCh4 has the higher correlation with profits. Moreover, 
the Spearman rank correlation coefficient between the yearly SSh (using IPCh4) and 
a firm’s profits is 0.810 (p = 0.015). This value can also be described as “very 
strong”. 
4.4.4  Differences of Yearly Sh and SSh Indices of Firms between Two 
Different Profit Groups
Tables 6 and 7 present the results of a longitudinal observation combined with a 
nested case-control design. Obviously, the yearly Sh and SSh indices of firms in 
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Group HP are much bigger than those in Group LP during the period 1990–2005; 
these differences are significant. We note that the same statistical significances of 
paired differences are valid for results of Sh indices as well as for SSh indices.
Table 6. Results of paired differences tests of firms’ yearly Sh between Group H and Group L (based on 
IPCh4).
Paired differences 95% confidence interval of the difference
Pairs- Sh Mean Std. Deviation Lower Upper t-value df Sig. (2-tailed)
GHR1 - GLR1 144.250 45.918 119.782 168.718 12.566 15 0.000
GHR2 - GLR2 126.938 34.555 108.524 145.351 14.694 15 0.000
GHR3 - GLR3 158.000 46.286 133.336 182.664 13.654 15 0.000
GHR4 - GLP4 105.688 26.630  91.497 119.878 15.875 15 0.000
Table 7. Results of paired differences tests of firms’ yearly SSh between Group H and Group L (based on 
IPCh4).
Paired differences 95% confidence interval of the difference
Pairs- SSh Mean Std. Deviation Lower Upper t-value df Sig. (2-tailed)
GHR1 - GLR1 8.188 2.331 6.94560 9.429 14.052 15 0.000
GHR2 - GLR2 7.422 2.700 5.98329 8.861 10.996 15 0.000
GHR3 - GLR3 6.975 2.213 5.79602 8.154 12.610 15 0.000
GHR4 - GLR4 6.963 1.570 6.12586 7.799 17.738 15 0.000
Table 5. Correlations among yearly Sh and yearly SSh on the one hand and a firm’s profits on the other.
Company
Profits 
2006–2010
millions of 
US dollars
(Average)
Rank profits 
2006–2010
Yearly Sh 
Yearly SSh
Using IPCh4 Using IPCh3
Yearly Sh
(Mean) Rank Sh
Yearly Sh 
(Mean) Rank Sh
Yearly SSh
(Mean) Rank SSh
Johnson 
& Johnson
11451.00 1 234.31 2 170.19 2 17.15 1
Pfizer 10461.00 2 162.63 3 101.25 4 12.09 4
Merck  6610.02 3 246.19 1 175.19 1 16.98 2
Bristol-Myers 
Squibb
 4521.80 4 158.81 4 106.25 3 13.71 3
Amgen  3718.20 5  90.06 6  53.94 6  8.96 6
Biogen Idec   554.10 6  35.69 8  24.36 8  4.66 8
Allergan   395.24 7  88.19 5  61.31 5 10.00 5
Genzyme   349.72 8  53.13 7  35.75 7  6.75 7
Spearman 
correlation
0.857** 0.762* 0.810*
Note. ** Correlation is significant at the 0.01 level (2-tailed); * Correlation is significant at the 0.05 level 
(2-tailed).
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Figure 1 shows average profit values as a function of average Sh(Y) values (using 
IPCh4). As the Pearson correlation R is about 0.83, the rank correlation of Table 2 
as well as the results shown in Table 5 are logical consequences of this relation. 
Note that, although this figure consists of just eight points, each of them is the result 
of thousands of values.
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Figure 1. Functional relation between the Sh(Y) values and profi ts.
5 Discussion and Conclusions
In many scientific fields, it is difficult to collect large samples to perform an 
“ideal” real-world investigation. Therefore, special approaches are developed and 
carefully designed for small samples. In this contribution we included a nested case-
control approach, a method often used in the medical sciences, and applied it to 
improve the methodology used in patent research. By way of discussion we address 
the following issues.
5.1  The New Sh(Y) Index Indicates the Primary Competitive Strength of 
a Firm’s Patent Portfolio
Compared to the case of IPCh3, Sh based on IPCh4 can better indicate a firm’s 
innovative activities, measured through patents, as well as their technological 
breadth, and map the potential market value of patents. Instead of the yearly 
h-indices which may represent a firm’s innovation activities and their influence, the 
Sh(Y) index, proposed in our investigation, can reflect a firm’s innovation activities, 
its technological breadth, and its influence in an integrated way. As such the new 
index reflects the primary structure of a firm’s patents and their influence and is an 
indicator for the “weight” related to primary competitive strength of a firm’s patent 
portfolio (with significant correlation to a firm’s profits).
5.2 The Breadth of Patent is a Primary Structure Affecting Its Performance
Although SSh(Y) is a comprehensive indicator for the “weight” of the essential, 
competitive strength of a firm’s patent portfolio (including the depth of patents), 
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and although the relation between SSh(Y) and a firm’s profits is also significant, it 
does not have the same “strong” correlation as the Sh(Y) index does, which suggests 
that the breadth of a patent is the primary structure affecting a patent performance. 
The depth of a patent plays a smaller role in a firm’s profit. The Spearman rank 
correlation coefficient between the yearly Dh and a firm’s profits is 0.690 (p = 
0.058), while this correlation between the yearly average depth of patents and a 
firm’s profits is -0.024, and hence is not significant (Appendix Tables A5 and A7).
5.3 The h-core Reflects Market Value and Technological Value
The first h items in a firm’s patent list, known as its h-core, reflect market value 
and technological value. These core patents are closely related to the competitive 
strength of a company. Although there are multiple dimensions involved in the 
innovative performance of a firm, the core competitive strength of a company is 
highly dependent on the performance of patents (Hagedoorn & Cloodt, 2003), one 
aspect being that patents are transferable, so that the patent assignee benefits in 
monetary terms from their purchase (Lee, 2009; Palokangas, 2011). 
Our work further leads to the suggestion to different sized firms to include policy-
making on technological innovation in its management. This is because there is 
always a limited R&D capital in a company. Indeed, we also found out that the 
Spearman correlation coefficient between the yearly average number of 4-digit 
codes of patents and a firm’s profits is even negative (namely –0.310, Appendix 
Tables A6 and A7), suggesting that a firm’s profits are highly dependent on the first 
h items of a firm’s patents rather than the “average patent” (Palokangas, 2011; 
Reitzig, 2003). The fact that a small group of patents essentially determines the 
competitive strength of a company is yet another example of the law of the vital 
few, also known as the 80–20 rule. In this sense, we claim that the structural h-index 
proposed in this study will be beneficial for modelling an optimal patent system.
Patent evaluation is a complicated issue which requires taking a full picture from 
different perspectives. This preliminary study proposes a new and simple indicator 
for gauging a company’s patent portfolio. Positive results are backed by evidence 
based on a large dataset from the pharmaceutical industry. Of course, we are aware 
that this is just a case study and, moreover, that any R&D indicator is at best PAC, 
as put forward in the case of citation indicators by Rousseau (2016). We are 
convinced though that the structural h-index is a useful addition to the field of 
patentometrics. 
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Appendix A
Table A1. Yearly h-indices for eight companies during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 32 23 25 17  8  1 11  4
1991 29 24 31 23 12  0 20  4
1992 29 27 32 20 10  1 20  5
1993 32 22 32 25  7  1 19  4
1994 31 25 30 26 13  6 17  7
1995 30 18 30 27 14  2 23  7
1996 41 24 35 26 14  2 21 14
1997 39 20 33 23 16  6 19 14
1998 40 29 35 29 15 11 14 15
1999 40 28 34 32 13  7 14 16
2000 29 30 25 29 14 14 16 15
2001 27 26 26 31 12 10 26 13
2002 39 28 30 26 14 13 23 10
2003 26 25 37 27 17  8 18 10
2004 30 22 37 27 15 11 18 11
2005 36 18 30 19 13  8 17  5
Table A2. Yearly IPCh4 for eight companies during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 6 7 6 5  4 1 4 3
1991 6 6 6 6  6 0 5 3
1992 5 6 7 5  4 1 5 4
1993 7 6 8 5  5 1 4 3
1994 7 6 8 7  6 5 5 5
1995 8 6 8 6  6 2 4 5
1996 8 5 8 6  6 2 4 6
1997 8 7 8 6  8 5 5 5
1998 7 6 8 6  8 6 5 6
1999 6 7 8 6  6 5 4 6
2000 7 8 8 7  7 5 4 6
2001 7 8 8 6 10 6 5 6
2002 7 9 8 8 10 7 5 6
2003 9 7 9 7  8 7 6 6
2004 7 6 8 7  7 6 5 6
2005 8 6 9 6  7 7 6 6
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Table A3. Yearly IPCh3 for eight companies during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 5 4 4 4 3 1 3 2
1991 5 5 5 4 3 0 4 3
1992 4 4 5 4 3 1 4 3
1993 5 4 6 4 3 1 3 2
1994 5 4 6 4 3 3 3 3
1995 5 3 5 4 4 2 3 3
1996 6 4 5 4 4 2 3 4
1997 6 4 6 4 4 4 3 4
1998 5 4 5 4 5 4 3 4
1999 4 4 6 4 4 3 3 4
2000 5 5 6 4 5 4 3 4
2001 5 4 5 4 5 4 3 4
2002 5 5 6 5 5 4 3 4
2003 6 4 6 5 5 5 4 4
2004 5 4 6 4 4 4 4 4
2005 6 4 7 5 5 5 4 3
Table A4. The yearly h-index of patent depth (Dhy) for eight companies during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990  3 6  5  3 3 1 2 2
1991  4 6  5  4 3 0 4 2
1992  4 5  6  3 4 1 3 3
1993  3 5  6  4 4 1 4 2
1994  3 6 10  4 4 2 3 3
1995  4 4  6  5 3 1 4 3
1996  4 6  6  4 4 1 3 4
1997  4 5  6  6 6 3 4 4
1998  8 6  5  4 6 3 3 5
1999  9 6  5  6 5 2 4 6
2000  9 7  6  6 6 4 3 7
2001 10 8  7  6 8 4 3 6
2002  4 8  7 10 8 5 4 5
2003  5 8  8  7 8 3 4 6
2004  6 7  8  7 7 4 4 6
2005  6 8  8  6 8 4 4 4
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Table A5. Yearly average depth of patents (average dad) for eight companies during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 1.50 2.49 1.79 1.77 2.04 4.22 1.44 2.29
1991 1.72 2.53 1.67 1.76 2.81 0.00 1.80 2.13
1992 1.59 2.35 1.93 1.67 2.86 2.83 1.48 2.39
1993 1.63 2.59 1.86 1.79 3.94 2.28 1.79 2.52
1994 1.52 2.47 2.58 1.70 3.71 2.53 1.62 2.00
1995 1.80 2.01 2.01 2.04 2.10 1.66 1.74 2.01
1996 1.78 2.63 2.01 1.75 2.29 3.63 1.66 2.85
1997 1.67 2.61 1.95 1.82 2.65 2.89 2.07 2.40
1998 2.22 3.01 2.01 1.73 3.15 2.82 1.53 3.18
1999 2.24 2.86 2.08 2.12 2.89 2.41 2.17 2.72
2000 2.38 3.14 2.22 2.40 2.93 3.33 1.68 3.44
2001 2.74 3.41 2.26 2.56 2.47 3.54 1.68 3.05
2002 1.69 3.06 2.33 3.34 3.65 3.18 2.03 2.30
2003 1.77 3.19 2.46 2.73 3.50 2.42 1.81 2.69
2004 1.93 2.86 2.65 2.48 3.99 2.78 1.99 2.57
2005 2.016 2.67 2.64 2.31 3.96 3.01 2.00 2.01
Mean 1.887 2.743 2.153 2.123 3.059 2.721 1.781 2.543
Rank 7 2 5 6 1 3 8 4
Table A6. Yearly average number of 4-digit IPC codes (ave IPC-4 codes) of patents for eight companies 
during the period 1990–2005.
Year Johnson & Johnson Pfizer Merck
Bristol-Myers 
Squibb Amgen
Biogen 
Idec Allergan Genzyme
1990 2.85 2.81 2.83 2.76 3.46 9.00 2.58 2.67
1991 3.14 2.92 2.95 2.86 4.47 0.00 2.51 4.00
1992 2.37 2.60 3.00 2.72 3.63 6.00 2.84 3.91
1993 2.99 2.86 2.75 2.75 4.08 7.00 1.97 2.55
1994 2.98 2.75 2.72 2.97 4.17 6.00 2.54 4.07
1995 3.19 2.89 3.06 3.02 4.39 7.50 2.50 3.50
1996 3.52 2.94 3.07 2.83 4.08 6.50 1.94 3.57
1997 3.43 3.50 2.94 2.74 4.92 6.60 2.50 3.67
1998 2.60 3.60 3.12 2.59 4.64 5.56 2.36 3.08
1999 2.33 3.62 3.31 2.61 3.88 4.36 2.43 3.23
2000 2.96 3.78 3.47 3.14 4.08 4.57 2.18 3.49
2001 3.07 3.78 3.52 3.08 5.62 4.72 2.16 3.17
2002 2.78 3.72 3.74 3.55 6.06 4.74 2.43 3.57
2003 2.26 3.42 3.67 3.33 4.99 5.91 2.71 3.12
2004 2.91 2.97 3.48 3.04 4.66 4.51 2.56 3.29
2005 2.91 2.70 3.76 3.02 3.93 4.82 2.76 3.42
Mean 2.89 3.18 3.21 2.94 4.44 5.49 2.44 3.39
Rank 7 5 4 6 2 1 8 3
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Table A7. Correlations among yearly average IPC-4 codes and yearly average dad of patents and a firm’s 
profits.
Company Rank profits 2006–2010
Yearly average IPC-4 codes Yearly average dad
Mean Rank Mean Rank
Johnson & Johnson 1 2.89 7 1.887 7
Pfizer 2 3.18 5 2.743 2
Merck 3 3.21 4 2.153 5
Bristol-Myers Squibb 4 2.94 6 2.123 6
Amgen 5 4.44 2 3.059 1
Biogen Idec 6 5.49 1 2.721 3
Allergan 7 2.44 8 1.781 8
Genzyme 8 3.39 3 2.543 4
Spearman correlation –0.310 –0.024
